Gilead to raise price for new hepatitis C drug above $84,000
September 12, 2014 at 18:46 PM EDT
LOS ANGELES, Sept 12 (Reuters) - The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.
